Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

Antti Siltanen

Analyst

Antti Siltanen portrait

Coverage

Herantis PharmaNexstimFaron PharmaceuticalsNightingale HealthBioretecBiohitOrionModulight

Latest content

ShowingAll content types

We take advantage of Biohit's January sale

Research 16.01.2026, 08.32 by Antti Siltanen
Biohit

Orion: Nubeqa – ustoppelig fremgang

Research 15.01.2026, 06.00 by Antti Siltanen
Orion

Stærk guidance fra Orion for 2026

Analyst Comment 14.01.2026, 08.24 by Antti Siltanen
Orion

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account

Herantis: Biomarker analysis completed successful Phase I

Research 09.01.2026, 10.01 by Antti Siltanen
Herantis Pharma

Herantis' latest analysis reveals HER-096's activity in central nervous system

Analyst Comment 08.01.2026, 08.44 by Antti Siltanen
Herantis Pharma

Nexstim: A solid end to a record year

Research 05.01.2026, 09.27 by Antti Siltanen
Nexstim

Herantis Pharma Extensive Report: Aiming for preliminary efficacy studies

Extensive research 22.12.2025, 11.40 by Antti Siltanen
Herantis Pharma

Another welfare services country is piloting Nightingale's technology

Analyst Comment 18.12.2025, 18.54 by Antti Luiro, Antti Siltanen
Nightingale Health

New study on benefits of Nightingale blood test in identifying cardiovascular disease risk

Analyst Comment 18.12.2025, 09.14 by Antti Luiro, Antti Siltanen
Nightingale Health

Investing in the life science sector

Video 18.12.2025, 07.47 by Antti Siltanen, Pia Maljanen
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.